Ligand Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ligand Pharma (LGND) Tops Q2 EPS by 25c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
August 6, 2018 4:03 PM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.59, $0.25 better than the analyst estimate of $2.34. Revenue for the quarter came in at $90 million versus the consensus estimate of $82.2 million.
The second quarter was punctuated by major positive corporate events that are driving our financial success and highlighting the potential of our business... More
